Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug

Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. Its principal mechanism of action seems to be through enhancing the T suppressor/T helper lymphocyte ratio. However, the molecular basis for these actions remains unclear. In this study it...

Descripción completa

Detalles Bibliográficos
Autores principales: Padrón, J., Rojas, A., Glaría, L., Caveda, L., Delgado, R., Torres, M., Martínez, O., López, E., Beltrán, A., Palacios, M.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365655/
https://www.ncbi.nlm.nih.gov/pubmed/18475666
http://dx.doi.org/10.1155/S0962935195000597
_version_ 1782154198052241408
author Padrón, J.
Rojas, A.
Glaría, L.
Caveda, L.
Delgado, R.
Torres, M.
Martínez, O.
López, E.
Beltrán, A.
Palacios, M.
author_facet Padrón, J.
Rojas, A.
Glaría, L.
Caveda, L.
Delgado, R.
Torres, M.
Martínez, O.
López, E.
Beltrán, A.
Palacios, M.
author_sort Padrón, J.
collection PubMed
description Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. Its principal mechanism of action seems to be through enhancing the T suppressor/T helper lymphocyte ratio. However, the molecular basis for these actions remains unclear. In this study it was found that CCA inhibits the production of guanosine 3',5'-cyclic monophosphate almost completely when present in concentrations of 1 mM. Further results demonstrated that such inhibition could also be explained by interference in constitutive nitric oxide generation. In addition to previous findings, more insight into the molecular mechanism of action of CCA is provided.
format Text
id pubmed-2365655
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-23656552008-05-12 Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug Padrón, J. Rojas, A. Glaría, L. Caveda, L. Delgado, R. Torres, M. Martínez, O. López, E. Beltrán, A. Palacios, M. Mediators Inflamm Research Article Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. Its principal mechanism of action seems to be through enhancing the T suppressor/T helper lymphocyte ratio. However, the molecular basis for these actions remains unclear. In this study it was found that CCA inhibits the production of guanosine 3',5'-cyclic monophosphate almost completely when present in concentrations of 1 mM. Further results demonstrated that such inhibition could also be explained by interference in constitutive nitric oxide generation. In addition to previous findings, more insight into the molecular mechanism of action of CCA is provided. Hindawi Publishing Corporation 1995-09 /pmc/articles/PMC2365655/ /pubmed/18475666 http://dx.doi.org/10.1155/S0962935195000597 Text en Copyright © 1995 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Padrón, J.
Rojas, A.
Glaría, L.
Caveda, L.
Delgado, R.
Torres, M.
Martínez, O.
López, E.
Beltrán, A.
Palacios, M.
Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
title Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
title_full Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
title_fullStr Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
title_full_unstemmed Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
title_short Lobenzarit disodium inhibits the constitutive NO–cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
title_sort lobenzarit disodium inhibits the constitutive no–cgmp metabolic pathways. possible involvement as an immunomodulatory drug
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365655/
https://www.ncbi.nlm.nih.gov/pubmed/18475666
http://dx.doi.org/10.1155/S0962935195000597
work_keys_str_mv AT padronj lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT rojasa lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT glarial lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT cavedal lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT delgador lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT torresm lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT martinezo lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT lopeze lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT beltrana lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug
AT palaciosm lobenzaritdisodiuminhibitstheconstitutivenocgmpmetabolicpathwayspossibleinvolvementasanimmunomodulatorydrug

Ejemplares similares